IDH3A and cancer: IDH3α depletion promotes hypermethylation of cancer-relevant genes and reduces cancer progression, suggesting that targeting IDH3 or the interaction of cSHMT and IDH3α could hold therapeutic potential for glioblastoma (May et al. 2019).